Stock Market & Financial Investment News

News Breaks March 13, 2013 15:16 EDT MYL Mylan announces Fortamet settlement agreement Mylan announced that its subsidiary, Mylan Pharmaceuticals, has entered into a settlement agreement with Shionogi and Andrx that will resolve patent litigation related to Metformin Hydrochloride Extended-release Tablets USP, 500 mg and 1000 mg. This product is the generic version of Shionogi's Fortamet, and is indicated as an adjunct to diet and exercise to lower blood glucose. Under the terms of the settlement agreement, Mylan may launch a generic version of Fortamet on August 1, or earlier under certain conditions. Pursuant to the agreement, pending litigation will be dismissed. All other terms and conditions of the settlement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission. News For MYL From The Last 14 Days Check below for free stories on MYL the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 18, 2013 08:36 EDT MYL Elan shares could be worh $19 in a buyout, says Jefferies Jefferies raised its price target for shares of Elan (ELN) to $19 from $14, reflecting what it sees as the value of the company in a takeout scenario. The firm says Elan management suggested they would be open to sale in the $15-$20 per share range. Jefferies believes a high taxpaying suitor could pay the upper end of that range, and lists Allergan (AGN), Regeneron (REGN), Vertex (VRTX), Alexion (ALXN), Zoetis (ZTS), Mylan (MYL) and Perrigo (PRGO) as potential acquirers for Elan. Shares of Elan are up 13c to $13.62 in pre-market trading after Royalty Pharma announced that its buyout proposal for the company has expired. June 17, 2013 13:20 EDT MYL Supreme Court rules generic drug makers can be sued over 'pay to delay' Subscribe for More Information 11:54 EDT MYL Supreme Court ruling a modest negative for generics, says Leerink Subscribe for More Information 08:36 EDT MYL InSite Vision to join Merck, Pfizer patent suit against Mylan InSite Vision (INSV) announced that it will join Merck (MRK) and Pfizer (PFE) in filing a patent infringement lawsuit against Mylan Pharmaceuticals (MYL). Mylan recently filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking to market a generic version of AzaSite before expiration of the patents covering AzaSite and its use. AzaSite is marketed by Merck in the U.S. On May 26, 2011, InSite and Merck filed a similar patent infringement lawsuit against Sandoz. A trial date for the Sandoz ANDA suit has been set for July 11, 2013. The companies have agreed that Merck will take the lead in prosecuting both lawsuits. Each company will be responsible for their own legal costs, with InSite assuming a monitoring role, the company said. June 13, 2013 17:23 EDT MYL Mylan files automatic mixed securities shelf Subscribe for More Information June 12, 2013 13:47 EDT MYL Mylan sees buying back stock in near future, Bloomberg says Subscribe for More Information 13:31 EDT MYL Mylan could be interested in generic assets split from Pfizer, Bloomberg says 13:28 EDT MYL Mylan chairman said explored possible Hospira deal Bloomberg says Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.